John has been working in the ion channel field for over 20 years. He received his PhD from the University of Bristol where he investigated the role of hERG in drug-induced cardiotoxicity.

Following two post doctorates at the University of Bristol, John moved to Xention where he helped establish a new drug discovery project focused on an ion channel target in atrial fibrillation, while also working on projects focused on identifying new therapeutics for neuropathic pain and autoimmune diseases.

After receiving an MPhil in Bioscience Enterprise from the University of Cambridge, John moved into a business development role at Xention where he successfully identified a partner for Xention’s Kv1.3 programme.

John has a mixed role at Metrion which includes leading Metrion’s Client Services team alongside contributing to a number of commercial activities, such as business development and strategic partnerships.